Group 1 - The company plans to globally offer 41.198 million shares, with 4.12 million shares for Hong Kong and 37.078 million shares for international sale [1] - The subscription period is from September 26 to October 2, with a maximum offer price of HKD 14.75 per share and an entry fee of approximately HKD 7,449.38 for 500 shares [1] - The total expected fundraising amount is HKD 608 million, with a net amount of HKD 525 million, aimed at funding the ongoing R&D, clinical development, and commercialization of inhalation formulation candidates [1] Group 2 - The company is focused on the research, production, and commercialization of inhalation technology and drugs, specifically targeting respiratory diseases [1] - The product portfolio strategically aligns with four of the top ten global inhalation drugs projected for 2024, with total sales revenue of USD 4.1 billion [1] - The company has reported net profits of CNY 31.726 million, CNY 21.088 million, and CNY 12.815 million for the fiscal years 2023, 2024, and the first quarter of 2025, reflecting year-on-year changes of 164.22%, -33.53%, and 108.31% respectively [2]

Group 1 - The company, Changfeng Pharmaceutical, plans to conduct an initial public offering (IPO) from September 26 to October 2, 2025, offering 41.198 million H-shares at a price of HKD 14.75 per share, with 10% allocated for Hong Kong and 90% for international sales [1] - The company specializes in the research, development, production, and commercialization of inhalation technology and drugs, focusing on respiratory diseases, and has received six product approvals from the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA) [1] - The company's revenue for the years 2022, 2023, 2024, and the three months ending March 31, 2025, were RMB 349 million, RMB 556 million, RMB 608 million, RMB 140 million, and RMB 136 million, respectively, with gross profits of RMB 268 million, RMB 458 million, RMB 491 million, RMB 115 million, and RMB 108 million [1] Group 2 - Assuming the offering price of HKD 14.75 per share, the company estimates to raise approximately HKD 525 million in net proceeds from the global offering [2] - The estimated net proceeds will be allocated as follows: approximately 40% for ongoing research and development of inhalation formulation candidates, 20% for preclinical research of various pipeline programs and technologies, 30% for expansion and upgrading of production facilities and equipment, and 10% for working capital and other general corporate purposes [2]